ArticleJournal of molecular graphics & modelling2020

Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.

Ikechukwu Achilonu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.